Welcome to our dedicated page for ZEAL news (Ticker: ZEAL), a resource for investors and traders seeking the latest updates and insights on ZEAL stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect ZEAL's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of ZEAL's position in the market.
Zealand Pharma A/S (Nasdaq: ZEAL) announced the termination of its Deposit Agreement for American Depositary Shares (ADSs), effective November 2, 2022. ADR Holders must surrender their ADSs by November 7, 2022, to acquire the underlying shares, incurring a cable fee of $17.50 and a cancellation fee of up to $0.05. After this date, the Depositary may sell the underlying shares, requiring ADR Holders to surrender their ADRs to receive sale proceeds, less any fees. This decision impacts holders of Zealand’s ADSs and reflects the company's focus on streamlining operations.
Zealand Pharma has announced its plan to voluntarily delist its American Depositary Shares (ADS) from the Nasdaq Global Select Market. This decision aims to consolidate trading on Nasdaq Copenhagen, enhancing liquidity and operational efficiency. Currently, the ADSs represent less than 1.5% of the total share capital. Zealand intends to file the necessary forms with the SEC to facilitate this delisting, expected to conclude by the end of Q3 2022. The firm reaffirms its commitment to prioritize R&D while maintaining compliance with financial regulations.
Zealand Pharma A/S (Nasdaq: ZEAL) will host a conference call on August 11, 2022, at 4 pm CET (10 am ET) to present its second quarter results for 2022. Key executives, including President Adam Steensberg and CFO Matt Dallas, will present and answer questions. The event will be conducted in English, and access can be gained through registration. Zealand focuses on innovative peptide-based medicines, with more than 10 drug candidates in clinical development, two of which are already on the market.
Zealand Pharma A/S (NASDAQ: ZEAL) announced its total number of shares and voting rights as of June 30, 2022, following changes to its share capital. The company reported a total of 46,526,510 shares and voting rights, reflecting its capital structure post-private placement. Zealand, a biotechnology firm specializing in peptide-based medicines, has advanced multiple drug candidates into clinical development. The announcement complies with the Danish Capital Markets Act and aims to inform shareholders about the company's updated share metrics.
Iktos announced a collaboration with Zealand Pharma (NASDAQ: ZEAL) to co-develop AI technologies for peptide drug design. This partnership leverages Iktos' machine learning capabilities and Zealand's expertise in peptide discovery. The collaboration aims to enhance drug discovery processes through Iktos’ state-of-the-art modeling technology, focusing on designing novel peptide therapeutics. Both companies are dedicated to improving the efficiency of drug development, with Zealand contributing its extensive knowledge in peptide drugs.
Zealand Pharma (Nasdaq: ZEAL) announced transactions in its securities by managerial personnel on June 15, 2022. The company, based in Copenhagen and focusing on peptide-based medicines, highlighted its advancements in drug candidates, with two currently marketed and three in late-stage development. Zealand Pharma has entered into collaborations with Boehringer Ingelheim and AstraZeneca. The announcement included a caution regarding forward-looking statements, noting risks that could affect future results.
Zealand Pharma (NASDAQ: ZEAL) has announced a notification from Credit Suisse Group AG regarding a change in its shareholding. The major shareholder has reduced its stake to below the 5% threshold of Zealand's total share capital and voting rights. This change is in compliance with Section 38 of the Danish Capital Markets Act. Zealand, based in Copenhagen, focuses on developing innovative peptide-based medicines, with two products on the market and three in late-stage development.
Zealand Pharma presented promising data from its Phase 1 trial of dapiglutide at the 82nd Annual American Diabetes Association Scientific Sessions. Results indicated a dose-dependent weight loss of up to 4.3% of baseline body weight after four weeks, with no serious adverse events reported. The company announced plans to progress dapiglutide into a Phase 2 trial for obesity, anticipated to start by early 2023. Zealand continues to focus on innovative peptide-based therapeutics aimed at treating obesity, showing a commitment to its pipeline development.
Zealand Pharma has successfully registered a capital increase of 2,892,368 new shares with the Danish Business Authority. This capital boost, achieved through a Private Placement, raises Zealand's total share capital to DKK 46,526,510. The new shares will rank pari passu with existing shares and are expected to be traded on Nasdaq Copenhagen starting 7 June 2022. Danske Bank A/S and Nordea Danmark act as joint global coordinators for this offering.
Zealand Pharma A/S (Nasdaq: ZEAL) will participate in two upcoming investor conferences in June 2022: the Jefferies 2022 Global Healthcare Conference on June 10 and the Goldman Sachs Global Healthcare Conference on June 13. The Jefferies presentation will start at 8:00 a.m. EST and will be available via a live webcast, which will be archived afterward on the company's website. Zealand Pharma focuses on developing peptide-based medicines, having advanced over 10 drug candidates into clinical development.
